This page is not the official website. Generated by AI, does not constitute any advice. If needed, please click here to visit the corresponding official website.

UNLOCKING siRNA'S POWER FOR NEXT-GEN THERAPIES

RONA THERAPEUTICS is a pioneering nucleic acid therapeutics company to discover, develop and deliver transformative modular RNA medicines to treat patients globally.

LEARN MORE

ABOUT RONA THERAPEUTICS

Rona Therapeutics is a world-leading nucleic acid therapeutics company dedicated to addressing metabolic and degenerative diseases.

Since its inception in 2021, Rona Therapeutics has advanced several potential best-in-class siRNA therapeutics in the clinic. With longer duration, deep knockdown and improved tolerability, Rona Therapeutics' metabolic assets have demonstrated a differentiated profile to address unmet needs in cardiovascular diseases, MASH and obesity.

The company has built a proprietary extrahepatic delivery platform in obesity and neurodegenerative diseases to fully exploit nucleic acid delivery potential beyond the liver. With robust knockdown potency and long-term duration (Q9M or longer), multiple assets are progressing into IND-enabling stage to treat complex diseases that cannot be treated with conventional modalities.

~$200M USD

Raised from global leading long-only funds and strategic partners

Rona Therapeutics Lab

Management Team

Leadership with deep expertise in biopharma, venture capital, and translational research

SS

Stella (Yibin) Shi

Chief Executive Officer

Founder with ~15 years of biopharmaceutical and venture capital experience, previously Managing Director at Lilly Asia Ventures.

AD

Alex M. DePaoli, M.D.

Chief Medical Officer

Executive Vice President of Translational Research, joined in January 2025.

JH

Jinyu Huang, Ph.D.

SVP of Chemistry

Senior leader in nucleic acid chemistry and drug development.

LP

Ling Pan, Ph.D.

EVP of Discovery & Research

Driving innovation in RNA discovery and preclinical development.

JY

Joshua (Jianhua) Yu, Ph.D.

VP of CMC

Expertise in chemistry, manufacturing, and controls for RNA therapeutics.

JT

Jasper (Zhuocheng) Tu

VP of Finance & Corp Dev

Led $200M+ in funding rounds and strategic partnerships.

Our Proprietary Platforms

Next-generation delivery systems enabling durable, targeted, and safe RNA therapeutics

GAIA: Liver Delivery Platform

Long dosing intervals to improve patient compliance

Convenient subcutaneous injection

Novel GalNAc and chemical modifications for improved potency and safety

APOLLO: Extrahepatic Delivery Platform

Small molecule conjugation for efficient receptor-mediated uptake in CNS

Intrathecal local delivery to minimize systemic side effects

Q6M or longer dosing with proof-of-concept in non-human primates

Bi-Valent/Multi-Valent: Plug-and-Play Scalable Platform

Ideal for complex diseases like cardiovascular disorders and obesity

Potential to treat multiple diseases via dual-targeting

Synergistic efficacy without added side effects; streamlined development

Our Pipeline

Innovative siRNA therapeutics targeting high-unmet medical needs

RN0361

Hypertriglyceridemia | ApoC3

Preclinical IND-Enabling Ph1 Ph2 Ph3

Long-acting APOC3-targeting siRNA. Presented Phase 1 data at AHA 2025. FDA IND approved for Phase 2 (Mar 2025).

RN3161

Obesity | INHBE

Preclinical IND-Enabling Ph1 Ph2 Ph3

Highly potent and durable INHBE siRNA. IND filed (Sep 2025). Targets obesity with long-acting mechanism.

RN5681

ASCVD | PCSK9-Lp(a)

Preclinical IND-Enabling Ph1 Ph2 Ph3

Dual-targeting siRNA for atherosclerotic cardiovascular disease. Early preclinical development.

RN0191

PCSK9 siRNA

Preclinical IND-Enabling Ph1 Ph2 Ph3

Innovative PCSK9 siRNA. First subject dosed in Australia (Aug 2023), IND approved in China (Dec 2023).

RN1871

Hypertension | AGT

Preclinical IND-Enabling Ph1 Ph2 Ph3

Novel angiotensinogen (AGT)-targeting siRNA. NMPA IND approved for Phase 1 (Apr 2025).

RN-XXXX

Neurodegenerative Disease

Preclinical IND-Enabling Ph1 Ph2 Ph3

Utilizing APOLLO platform for CNS delivery. Early-stage discovery.

RN-YYYY

MASH | Multi-Target

Preclinical IND-Enabling Ph1 Ph2 Ph3

Bi-valent siRNA targeting metabolic dysfunction in MASH. Preclinical optimization.

RN-ZZZZ

Kidney Disease | Glomerulonephritis

Preclinical IND-Enabling Ph1 Ph2 Ph3

Co-developed with Keymed. First-in-class siRNA for severe kidney diseases.

Latest News

Rona Therapeutics Presents Phase 1 Data for RN0361 at AHA 2025

October 11, 2025 — Data demonstrates significant ApoC3 knockdown and triglyceride reduction with favorable safety profile.

Press Release

Rona Therapeutics Announces IND Filing of RN3161 for Obesity

September 15, 2025 — Highly potent INHBE siRNA enters regulatory review for Phase 1 clinical trials.

Corporate Update

RN1871 Receives NMPA IND Approval for Hypertension Study

April 21, 2025 — Novel AGT-targeting siRNA approved to begin Phase 1 trials in China.

Regulatory
VIEW ALL NEWS

Contact Us

For business development, recruitment, and partnership inquiries

China

Tower 3, JNB Life Science Park, No.795, Kangwei Road, Pudong New Area, Shanghai, China

BD@ronatherapeutics.com

HR@ronatherapeutics.com

Australia

SE 2 202-220 FERNTREE GULLY RD, CLAYTON VIC 3168

BD@ronatherapeutics.com

United States

State of Delaware

BD@ronatherapeutics.com

Visit Official Website
China Quality Suppliers fobcompany.info

Notice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.

For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact support@fobcompany.info via your corporate email to cancel. We will cancel your inclusion within 3 business days.

如果您是域名所有者 不想被fobcompany.info收录 请用企业邮箱联系support@fobcompany.info 取消收录 我们将在3个工作日取消您的收录

Service Request: If you are other domain and want to be included, please contact support@fobcompany.info

如果您是其他域名合作 也请联系support@fobcompany.info